Archemix

About:

Archemix, a biotechnology company, develops and commercializes aptamer therapeutics for the treatment of chronic and acute diseases

Website: http://www.archemix.com

Top Investors: SV Health Investors, Atlas Venture, Highland Capital Partners, Schroder Ventures, Care Capital

Description:

Archemix Corp., a biotechnology company, engages in discovering, developing, and commercializing aptamer therapeutics for the prevention and treatment of chronic and acute diseases in Massachusetts. Its aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure. The company also offers product candidates for cardiovascular, hematology, and oncology diseases. Archemix Corp. was incorporated in 2000 and is based in Cambridge, Massachusetts.

Total Funding Amount:

$102M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2000-01-01

Contact Email:

archemix(AT)shareholderrep.com

Founders:

Jean-Francois Formela

Number of Employees:

51-100

Last Funding Date:

2004-04-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai